OliX Pharmaceuticals, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2010-02-26
- Employees
- 74
- Market Cap
- -
- Website
- http://www.olixpharma.com
Clinical Trials
4
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:3
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (75.0%)Phase 2
1 (25.0%)Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration
Phase 1
Recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- First Posted Date
- 2022-12-08
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT05643118
- Locations
- 🇺🇸
California Retina Consultants, Santa Maria, California, United States
🇺🇸University Retina, Oak Forest, Illinois, United States
🇺🇸The Retina Institute, Saint Louis, Missouri, United States
Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery
- First Posted Date
- 2021-05-07
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04877756
- Locations
- 🇺🇸
MedStar Health Research Institute, Washington, District of Columbia, United States
🇺🇸Miami Dermatology & Laser Research, LLC, Miami, Florida, United States
🇺🇸Miami Plastic Surgery, Miami, Florida, United States
A Study to Evaluate Safety and PK Profiles of OLX10010 in Healthy Subjects
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Olix Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT03569267
- Locations
- 🇬🇧
Covance Clinical Research Unit (CRU) Ltd., Leeds, United Kingdom
News
No news found